2013

/Tag:2013

Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes

Company Additionally Anticipates Results from Phase 2a FDA Study for Type 2 Diabetes in January JERUSALEM, Dec. 20, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today successful results in [...]

2018-05-30T17:04:30+00:00 Categories: Press Releases|Tags: |

Oramed Receives Allowance on its Core Oral GLP-1 Technology Patent in Israel

JERUSALEM, December 10, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM:ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received allowance for a key patent from the Israeli Patent Office. The patent, entitled "Methods and [...]

2018-05-30T17:04:30+00:00 Categories: Press Releases|Tags: |

Oramed Announces Last Patient Out in Phase 2a FDA Trial of its ORMD-0801 Oral Insulin Capsule

JERUSALEM, November 12, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the last patient has left the clinic from its U.S. FDA Phase 2a safety study for ORMD-0801, [...]

2018-05-30T17:04:31+00:00 Categories: Press Releases|Tags: |

Oramed Granted Patents in Japan and Canada for its POD™ Technology for the Oral Delivery of Proteins

Increases patent portfolio to 11 issued and 24 pending JERUSALEM, October 3, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has received two additional patent approvals for its platform Protein Oral Delivery (POD™) [...]

2018-05-30T17:04:31+00:00 Categories: Press Releases|Tags: |

Oramed to Participate in Barclays’ Israel Biotech Corporate Day in Zurich on September 30, 2013

JERUSALEM, September 25, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been invited to participate in an exclusive Israeli Biotech Corporate Day, hosted by Barclays on September 30, 2013 in Zurich, Switzerland.  [...]

2018-05-30T17:04:32+00:00 Categories: Press Releases|Tags: |

Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes

Company's 2nd product slated for U.S. clinical trials offers a more patient-friendly form of GLP-1 analog which had more than $2 billion USD in 2012 sales JERUSALEM, September 3, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, [...]

2018-05-30T17:04:40+00:00 Categories: Press Releases|Tags: |